期刊文献+

继发性嗜血细胞综合征15例临床分析 被引量:2

Clinical feature analysis of 15 cases with secondary hemophagocytic syndrome
原文传递
导出
摘要 目的探讨自身免疫病相关性与非自身免疫病相关性嗜血细胞综合征(HPS)两者的临床特征、治疗及预后。方法回顾性收集15例2008年1月至2010年6月我院风湿科及血液科住院的继发性嗜血细胞综合征患者,分析临床及实验室特征、治疗以及预后的关系。并比较自身免疫病相关性嗜血细胞综合征(A组)与非自身免疫病相关性嗜血细胞综合征(B组)之间的异同点。采用Fisher精确概率法、t检验和秩和检验。结果2组均表现出发热、出血、黄疸、肝脾肿大,A组特异性表现出关节痛、皮疹、自身抗体阳性,而B组中黄疸更常见(38%和100%,P=0.018)。但比较2组实验室指标及预后差异均无统计学意义(P〉0.05)激素联合免疫抑制剂和丙种球蛋白治疗预后更好(P〈0.05)。结论除黄疸外,自身免疫病相关性HPS与其他继发性HPS的临床表现及实验室指标无明显差异,激素联合免疫抑制剂及丙种球蛋白治疗有效。 Objective To investigate the clinical characteristics, treatment and prognosis of autoimmune diseases associated and non-autoimmune diseases associated hemophagocytic: syndrome. Methods Clinical records of 15 cases with secondary hemophagocytic syndrome' were collected and the relations with treatment and prognosis was analyze. The similarities and differences between autoimmune disease associated hemophagocytic syndrome (group A) and non-autoimmune disease associated hemophagocytic syndrome (group B) were compared. Fisher exact test, t test and Willcoxen test were used for statistical analysis. Results Both groups had fever, bleeding, jaundice, hepatosplenomegaly, and arthralgia, skin rash and positive of autoaptibodies in group A were discovered specifically. But in group B, the patients with icterus were more common (38% vs 100%, P=0.018). There was no significant difference in their laboratory data and prognosis when compared between the two groups (P〉0.05). The patients who received corticosteroids and IVIG and/or immunosuppressive agents had better prognosis (P〈0.05). Conclusion Except for ieterus there is no significant difference in clinical features and laboratory data among autoimmune disease associated hemophagocytic syndrome and other secondary hemophagocytic syndrome. And the therapy with corticosteroids combined with IVIG and/or immunosuppressive agents is effective.
出处 《中华风湿病学杂志》 CAS CSCD 北大核心 2011年第5期336-340,共5页 Chinese Journal of Rheumatology
关键词 组织细胞增多症 自身免疫疾病 生物医学研究 Histiocytosis Autoimmune diseases Biomedical research
  • 相关文献

参考文献11

  • 1Freeman HR, Ramanan AV. Review of haemophagocytic lymphohistiocytosis. Arch Dis Child, 2010, 95: 422-425.
  • 2Henter JI, Horne A, Arico' M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer, 2007, 48: 124-131.
  • 3Hadchouel M, Prieur AM, Griscelli C. Acute hemorrhagic, hepatic, and neurological manifestations in juvenile rheumatoid arthritis: possible relationship to drugs or infection. Pediatr, 1985, 106: 561-566.
  • 4Grom AA. Natural killer cell dysfunction: a common pathway in systemic-onset juvenile rheumatoid arthritis, macrophage activation syndrome, and hemophagocytic lymphohistiocytosis? Arthritis Rheum, 2004, 50: 689-698.
  • 5Sawhney S, Woo P, Murray KJ. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child, 2001, 85: 421-426.
  • 6Ravelli A, Magni-Manzoni S, Pistorio A, et al. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr, 2005, 146: 598-604. ".
  • 7Munira S, Lucas J, Lazarchick J, et al. Secondary hemophagocytic syndrome in adults: a case series of 18 patients in a single institution and a review of literature. Hematological Oncol,2010, 28: 156-160.
  • 8Kelly A, Ramanan AV. Recognition and management of macrophage activation syndrome in juvenile arthritis. Curr Opin Rheumatol, 2007, 19: 477-481.
  • 9Prahalad S, Bove KE, Dickens D, et al. Etanercept in the treatment of macrophage activation syndrome. J Rhemnatol, 2001, 28: 2120-2124.
  • 10Ravelli A, Carla MC, Buratti S, et al. Methotrexate as a possible trigger of macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol, 2001, 28: 865-867.

同被引文献4

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部